Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Lisa Graver
Person

Lisa Graver

Tracked across 2 events · 13 articles · First seen Apr 30, 2026 · Last active Aug 21, 2026

Sentiment
15
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
2 30
Regulatory
FDA closes Alvotech facility inspection
Impact: As CEO, Lisa Graver commented on the milestone, representing leadership's confidence in quality improvements.
Jul 29, 2026 · 7 articles
4 0
Business
Alvotech Lotus biosimilar licensing agreement
On August 21, 2026, Alvogen announced a strategic licensing and commercialization agreement with Rhythm Pharmaceuticals covering two biosimilar candidates: AVT34 (proposed biosimilar to Imfinzi/durvalumab) and AVT87 (proposed biosimilar to Hemlibra/emicizumab). Under the semi-exclusive U.S. agreement,…
Impact: As CEO of Alvogen, Lisa Graver announced the agreement and highlighted its strategic importance for the company.
Aug 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Lisa Graver live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.